PCI Pharma Services (PCI), a pharmaceutical and biopharmaceutical global outsourcing solutions provider, has completed an expansion to its Rockford, IL facility to enhance its specialty drug product capabilities.
 
The 30,000+ sq. ft. facility dedicated to specialty drug products now includes four high potent compound capable suites built to ISO8 standards. The suites are equipped with the latest in air-filtration technology—high-efficiency particle air (HEPA) filtration with 30 air turns per hour. PCI has also built three new secondary packaging areas to deliver increased scalability and installed three new coolers and a new freezer for -20°C to -8°C cold chain requirements.
 
“As we continue to see advancements in cancer and hormonal therapies, and growth in the allergen market, there is a stronger need in the marketplace for high potent compound suites,” said Angella Sutthiwan, vice president and general manager, PCI Pharma Services. “Our decision to expand this specialized service fuels our ability to support our growing client base and demonstrates why our clients continue to turn to PCI as the outsourcing partner they can trust for unmatched capacity and flexibility.”
 
This investment in Rockford comes on the heels of another expansion of the Rockford, IL facility in September to unveil a new state-of-the-art Clinical Center of Excellence.
 
“Across the globe, we are making strategic decisions that enable us to continue to support our clients’ business and meet increased demands for our integrated services,” said Salim Haffar, chief executive officer, PCI Pharma Services. “At PCI, we are committed to helping our clients get life-changing therapies into the hands of those who need it most, anywhere in the world. Our latest investment in the Rockford site is further evidence of our dedication to stay out in front of our clients’ needs and offer them the best and most innovative solutions in the industry.”